Journal profile · Gastroenterology & Hepatology
Inflammatory Bowel Diseases
ISSN 1078-0998 · eISSN 1536-4844 · Oxford University Press · UNITED STATES · Monthly
Inflammatory Bowel Diseases: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 5.34; hybrid open access; APC about USD 3,862; median 96 days to acceptance (109 articles, last 24 months); community-reported acceptance: about 20%; 517 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Inflammatory Bowel Diseases is published by Oxford University Press and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Inflammatory Bowel Disease, Microscopic Colitis and Autoimmune and Inflammatory Disorders, together about 56.1% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Inflammatory Bowel Diseases® supports the mission of the Crohn's & Colitis Foundation by publishing research that will improve the quality of life of patients and bring us closer to cures. Each issue contains original basic science, translational, and clinical research regarding pathogenesis, epidemiology, evaluation, and treatment of inflammatory bowel disease (IBD) that will lead to advancements in overall clinical care. Articles published in Inflammatory Bowel Diseases® are from clinicians and researchers around the world and highlight unique and important issues in adult and pediatric IBD. We seek to publish novel and innovative research that will have a positive impact on the lives of children and adults with IBD. The journal does not accept case reports. Inflammatory Bowel Diseases® is the official journal of the Crohn's & Colitis Foundation. We invite you to read more about the Foundation's mission and core values. Journal metrics Citation metrics Clarivate 2025 Impact Factor 5.5 2025 5 Year Impact Factor 5.7 Gastroenterology & Hepatology (Rank by Impact Factor) 30/153 Scopus 2025 CiteScore 9.2 Gastroenterology (Rank by CiteScore) 16/176 About metrics Disclaimer Statements of fact and opinion in the articles in Inflammatory Bowel Diseases are those of the respective authors and contributors and not of the Journal, Crohn's & Colitis Foundation, or Oxford University Press, unless otherwise expressly indicated. Neither Oxford University Press, Crohn's & Colitis Foundation, nor the Journal make any representation, express or implied, in respect of the accuracy of the material in the Journal and cannot accept any legal responsibility or liability for any errors or omissions that may be made. Readers should make their own evaluation as to the appropriateness or otherwise of the information included. Becoming digital-only Starting in January 2024, Inflammatory Bowel Diseases® will be transitioning to a digital-only format, shrinking our footprint while providing an even more immersive and immediate reading experience for you. Going digital demonstrates our commitment to top-notch, cutting-edge research while allowing us to enhance the content, interactivity, and accessibility of our journal, ensuring you have seamless access to the latest IBD updates. Embracing the digital frontier means readers will enjoy: Instant Access: No more waiting for your journal to arrive in the mail. Readers are guaranteed access to the most current versions of all articles at a
From the journal's Aims & Scope
Research area (LetPub): Gastroenterology & Hepatology
Editor-in-chief Sonia FriedmanPublisher website
Editorial board by country: 2 in mainland China (about 2%); most named United States 73, Italy 4, United Kingdom 3, Canada 3, Mainland China 2 (101 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Inflammatory Bowel DiseaseBiochemistry, Genetics and Molecular Biology36.3%
- Microscopic ColitisMedicine15.2%
- Autoimmune and Inflammatory DisordersMedicine4.5%
- Gut microbiota and healthBiochemistry, Genetics and Molecular Biology4.3%
- Eosinophilic EsophagitisMedicine3.8%
- Gastrointestinal motility and disordersMedicine2.7%
- Helicobacter pylori-related gastroenterology studiesMedicine2.7%
- Liver Diseases and ImmunityMedicine2.6%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Gastroenterology & Hepatology | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Gastroenterology & Hepatology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Gastroenterology & Hepatology | Zone 3 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 5.34LetPub ·
- Impact factor (publisher) 2025
- 9.2Publisher website ·
- 5-year impact factor (publisher) 2025
- 5.7Publisher website ·
- CiteScore 2026-06
- 9.2LetPub ·
- CiteScore (publisher) 2025
- 9.2Publisher website ·
- SJR 2026-06
- 1.93LetPub ·
- SNIP 2026-06
- 1.5LetPub ·
- h-index
- 128LetPub ·
- h-index
- 211OpenAlex ·
- i10-index
- 5,239OpenAlex ·
- 2-year mean citedness
- 2.67OpenAlex ·
- Self-citation rate
- 5.5%LetPub ·
- Share of gold OA articles
- 28.53%LetPub ·
Volume
- Articles per year
- 221LetPub ·
Articles by year OpenAlex count · 13,369 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 355 | 99 | 81 |
| 2025 | 517 | 243 | 954 |
| 2024 | 509 | 404 | 2,658 |
| 2023 | 489 | 389 | 4,576 |
| 2022 | 473 | 313 | 4,834 |
| 2021 | 504 | 206 | 6,567 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
96 daysMedian, submission to acceptance · P25–P75 64 days – 146 days
- Acceptance to online
- median 28 days (50 articles)
- Submission to online
- median 128 days
- Sample
- 109 articles with submission and acceptance dates (819 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 1 monthLetPub ·
- Average acceptance (community reports)
- 20%LetPub ·
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 3,862 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
Other charges and waivers (author guidelines)
- Submission fee
- No submission fee
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare8 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- 3–5
- Manuscript length
- ≤ 7,000 words
- Reference style
- Numbered, in order of citation
- First submission
- Free format: the journal's layout is not required
- Highlights
- Required
- Graphical abstract
- Optional
- Cover letter
- Required
Article types accepted9
- brief reportBasic, translational, and clinical articles submitted to IBD should be submitted as one of the following article types using the parameters below. Review Articl…Length not stated
- brief reportsBrief Reports should be classified as either Basic Science, Translational, or Clinical and should be concise communications of original research.Length not stated
- letters to the editorLetters in response to articles published in the Journal are welcome.Length not stated
- original articleBasic, translational, and clinical articles submitted to IBD should be submitted as one of the following article types using the parameters below. Review Articl…Length not stated
- original articlesOriginal Articles should be classified as Basic Science, Translational, or Clinical, should add to the body of knowledge of Crohn's disease and ulcerative colit…Length not stated
- original researchBasic, translational, and clinical articles submitted to IBD should be submitted as one of the following article types using the parameters below. Review Articl…Length not stated
- reviewBasic, translational, and clinical articles submitted to IBD should be submitted as one of the following article types using the parameters below. Review Articl…Length not stated
- review articleBasic, translational, and clinical articles submitted to IBD should be submitted as one of the following article types using the parameters below. Review Articl…Length not stated
- review articlesReview Articles should be classified as Basic Science, Translational, or Clinical and should present recent advances in a relatively narrow topic that have been…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, Publication ethics, License & copyright, Open access, Peer review, Plagiarism, Preprints
- AI use
AI tools do not qualify as authors Model summary
Natural language processing tools driven by artificial intelligence (AI) do not qualify as authors, and the Journal will screen for them in author lists.
Source ↗Publisher website ·- Authorship Authorship
No ghost, guest, or gift authorship Model summary
Each person listed as an author is expected to follow the authorship criteria put forth by the ICMJE. Deceased persons who meet the criteria for inclusion as coauthors should be so included, with an Author Information note indicating the date of death. In submitting to IBD, authors are expected to honor all deadlines presented to them. Authors are expected to respond to all communication from the …
Source ↗Publisher website ·- Conflicts of interest Policies on Conflicts of Interest
IBD is committed to making transparent the Journal’s policies on Conflict of Interest as they relate to authors, reviewers, and editors. Authors should familiarize themselves with the below points as well as COPE’s Guidelines on Good Publication Practice before committing to working with the Journal. Conflicts in regard to publication can occur when a competing interest may influence or be perceiv…
Source ↗Publisher website ·- Data availability Availability of Data and Materials
Where ethically feasible, IBD strongly encourages authors to make all data and software code on which the conclusions of the paper rely available to readers. We suggest that data be presented in the main manuscript or additional supporting files, or deposited in a public repository whenever possible. For information on general repositories for all data types, and a list of recommended repositories…
Source ↗Publisher website ·- Publication ethics Ethical Considerations
Publication ethics per COPE Model summary
A submitted manuscript must be an original contribution not previously published (except as an abstract or preliminary report), must not be under consideration for publication elsewhere, and, if accepted, must not be published elsewhere in similar form, in any language, without the consent of the publisher. Deposition of manuscripts prior to submission on community preprint servers or on conferenc…
Source ↗Publisher website ·- License & copyright Exclusive License
It is a condition of publication in Inflammatory Bowel Diseases that authors grant an exclusive license to the Crohn’s & Colitis Foundation. This ensures that requests from third parties to reproduce articles are handled efficiently and consistently and will also allow the article to be as widely disseminated as possible. As part of the license agreement, authors may use their own material in othe…
Source ↗Publisher website ·- Open access Open Access Publication Fee Information
IBD offers the option of publishing under either a standard license or an Open Access license. Please note that some funders require Open Access publication as a condition of funding. If you are unsure whether you are required to publish Open Access, please do clarify any such requirements with your funder or institution. Should you wish to publish your article Open Access, you should select your …
Source ↗Publisher website ·- Peer review Peer Review
The Editors read all manuscript submissions. All manuscripts that meet the quality standards, are felt to advance the field, and adhere to the scope of the Journal are assigned to an Associate Editor and sent to outside experts for peer review using a single-anonymized system, meaning that authors’ identities are known to the Editor and to the reviewers, but that the reviewers’ identities are know…
Source ↗Publisher website ·- Plagiarism Plagiarism
All papers must be free of plagiarism. Plagiarism includes the unreferenced use of the author’s own work or ideas or the work or ideas of others, either published or unpublished. It may occur at any stage of the development of a manuscript and it applies to print and electronic versions of the work. Authors should consult the Committee on Publication Ethics’ (COPE) Guidelines on Good Publication P…
Source ↗Publisher website ·- Preprints
Preprint deposition allowed before submission Model summary
Deposition of manuscripts prior to submission on community preprint servers or on conference presentations online will not be considered prior publication and will not compromise potential publication in IBD.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Oxford University Press
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Monthly
- ISSN
- 1078-0998
- Electronic ISSN
- 1536-4844
- Society / sponsor
- Crohn's & Colitis Foundation
- Latest issue on the website
- Volume 32, Issue 9 (September 2026)
- Official links
- Journal homepage ↗LetPub
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Inflammatory Bowel Diseases
What CAS zone is Inflammatory Bowel Diseases in?
In the 2025 upgraded edition of the CAS Journal Ranking, Inflammatory Bowel Diseases is in Zone 3 of Medicine, and in Zone 3 of the minor category Gastroenterology & Hepatology. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Inflammatory Bowel Diseases?
The latest impact factor listed by LetPub is 5.34; CiteScore 9.2, h-index 211.
How long does peer review take at Inflammatory Bowel Diseases?
Based on the dates recorded on 109 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 96 days (interquartile range 64–146 days); authors report an average review time of about 1 month; the community-reported acceptance is “about 20%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Inflammatory Bowel Diseases?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: 3–5; Manuscript length: ≤ 7,000 words; Reference style: Numbered, in order of citation; First submission: Free format: the journal's layout is not required; Highlights: Required; Graphical abstract: Optional; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Inflammatory Bowel Diseases based?
Of the 101 board members whose country the journal's board page names, 2 (about 2%) are in mainland China; the countries named most often are United States (73), Italy (4) and United Kingdom (3). Counted from the institutions listed on the board page; for reference only.
Which databases index Inflammatory Bowel Diseases?
According to LetPub and DOAJ records, Inflammatory Bowel Diseases is indexed in SCIE and Scopus.
Is Inflammatory Bowel Diseases open access, and what is the APC?
Inflammatory Bowel Diseases is a hybrid journal. For open-access publication: APC about USD 3,862.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .